You Position: Home > Paper
STUDYING OF THE ASSOCIATION OF CELLULAR DRUG RESISTANCE IN VITRO WITH p170 EXPRESSION AND SPECIFIC CYTOGENETIC ABERRATIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
( views:273, downloads:4 )
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 6
- DOI:
- 10.3760/cma.j.issn.1009-9921.2004.06.002
- Key Word:
- 髓系白血病;急性;耐药;MTT分析;p170;细胞遗传学
Abstract： 目的:探讨急性髓系白血病(AML)患者体外细胞耐药与p170表达及染色体核型之间的关系.方法:用MTT分析方法检测阿糖胞苷(Ara-C)、柔红霉素(DNR)、高三尖杉酯碱(HHT)、安吖啶(AMSA)和米托蒽醌(MTZ)体外细胞耐药.间接免疫荧光染色检测p170蛋白表达水平.R显带分析染色体核型.结果:初治患者(138例)、难治患者(8例)、复发患者(14例)、慢性粒细胞白血病AML变(8例)和骨髓增生异常综合征AML变(8例),各组之间的p170蛋白表达水平和细胞耐药率无显著性差异(P＞0.05).p170表达率≥5%的患者Ara-C,DNR和MTZ耐药率明显高于p170表达率＜5%的患者,但HHT和AMSA的耐药检出率二者无显著性差异.p170表达水平与染色体核型异常无明显相关性.t(8;21)/inv(16)患者未发现对Ara-C有耐药.与正常核型组相比,5/7号染色体异常组的HHT和MTZ耐药发生率、+8组的HHT和DNR的耐药发生率、其他染色体异常组的Ara-C,DNR和HHT的耐药发生率明显增高(P＜0.05).结论:AML体外细胞耐药和p170蛋白表达水平与病期无关,p170表达率和特异染色体核型异常与体外细胞耐药有一定的相关性.
- [1]罗梅华.药敏试验MTT法对急性白血病化疗疗效的预示价值[J].1995,(1).
- [2]Jan Maxwell NØrgaard,Anne Bukh,Sven Tyge Langkjer,etc.MDR1 gene expression and drug resistance of AML cells[J].1998,100(3).
- [3]L, Pearson,C P, Leith,M H, Duncan,etc.Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8; 21) chromosomal translocation in pediatric acute myeloid leukemia.[J].1996,10.
- [4]Illmer T,Ehninger G,Harbich Brutscher E,etc.Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia and its implication in treatment outcome.[J].2002,87(5).
- [5]Mrozek K,Bloomfield CD,Heerema NA.Cytogenetics in acute leukemia.[J].2004,18(2).
- [6]Patrizia Tosi,Giuseppe Visani,Emanuela Ottaviani,etc.Inv(16) acute myeloid leukemia cells show an increased sensitivity to cytosine arabinoside <em>in vitro</em>[J].1998,60(3).
- [7]Smit EM,van-den-Heuvel-Eibrink MM,Schoester M,etc.MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7.[J].2001,15(3).
- [8]卞寿庚,郝玉书.成人急性非淋巴细胞白血病化疗的研究[J].1993,014 (2).
- [9]Styczynski J,Wysocki M.Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis.[J].2004,42(2).